Van ECK Associates Corp Purchases 10,419 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,818 shares of the biopharmaceutical company’s stock after acquiring an additional 10,419 shares during the period. Van ECK Associates Corp owned about 0.05% of Alnylam Pharmaceuticals worth $15,958,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ALNY. Huntington National Bank grew its holdings in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. SYM FINANCIAL Corp lifted its position in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 55 shares during the last quarter. Lindbrook Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 57 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock worth $1,532,000 after acquiring an additional 58 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 2.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company’s stock valued at $624,000 after acquiring an additional 63 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Raymond James upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $299.43.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $256.45 on Friday. The company’s 50 day moving average price is $254.03 and its two-hundred day moving average price is $263.35. The firm has a market capitalization of $33.08 billion, a P/E ratio of -97.88 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,964 shares of company stock worth $20,622,925. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.